A

Aravive Inc
F:VE11

Watchlist Manager
Aravive Inc
F:VE11
Watchlist
Price: 0.0325 EUR Market Closed
Market Cap: €2.4m

Net Margin

-674.5%
Current
Improving
by 249.2%
vs 3-y average of -923.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-674.5%
=
Net Income
$-39.9m
/
Revenue
$7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-674.5%
=
Net Income
€-39.9m
/
Revenue
$7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Aravive Inc
F:VE11
2.4m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 92% of companies in the United States of America
Percentile
8th
Based on 15 072 companies
8th percentile
-674.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Aravive Inc
Glance View

Market Cap
2.4m EUR
Industry
Biotechnology

Aravive, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The firm is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. The company is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.

VE11 Intrinsic Value
Not Available
A
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-674.5%
=
Net Income
$-39.9m
/
Revenue
$7m
What is Aravive Inc's current Net Margin?

The current Net Margin for Aravive Inc is -674.5%, which is above its 3-year median of -923.7%.

How has Net Margin changed over time?

Over the last 3 years, Aravive Inc’s Net Margin has decreased from -655.8% to -674.5%. During this period, it reached a low of -1 286.9% on Mar 31, 2023 and a high of -288.4% on Sep 30, 2021.

Back to Top